Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20. The randomized, double-blind study enrolled 145 patients in China with moderate to severe chronic spontaneous urticaria, or chronic hives, inadequately controlled by H1 antihistamines.
At week 12, complete hive resolution occurred in 54% of patients receiving 4 mg/kg CUE-221 versus 11% receiving placebo. The primary endpoint was met with a 43-percentage-point difference and p<0.005. For investors, the next question is whether relief lasting after treatment stops can give the drug a meaningful advantage over established options.
Read Also: Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
Bull Case
The results extend beyond hive counts. At the highest dose, 46% achieved complete response on the weekly urticaria activity score, meaning no hives or itching, compared with 11% on placebo. This key secondary endpoint was statistically significant at p<0.05.
CUE-221 targets IgE, an antibody involved in allergic reactions. It is designed to neutralize existing IgE while preserving a natural feedback pathway that can suppress new IgE production. That mechanism provides a rationale for investigating prolonged disease control.
Relief after treatment ended is the main commercial attraction. At week 28, twelve weeks after the final dose, 60% of the highest-dose group had complete hive resolution, compared with 24% of the omalizumab group. The 36-percentage-point difference came from a post hoc analysis, with reported p<0.05.
If replicated in a larger trial, sustained relief could support less frequent treatment and give physicians a reason to consider switching patients. Omalizumab, marketed as Xolair, is approved for this condition with injections every four weeks. Longer intervals between treatments could strengthen the case with patients and payers.
Cue Biopharma, Inc. reported no treatment-related serious adverse events or hypersensitivity reactions, including anaphylaxis. Management plans a Phase 2b/3 study intended to support registration.
Also read: Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?
Bear Case
The trial tested superiority over placebo, with no planned statistical comparison against omalizumab. Its week-12 efficacy table included 35 patients at the highest CUE-221 dose and 17 on omalizumab. Small groups make estimates sensitive to individual outcomes.
The later analysis identifies a potential advantage for a future comparison planned in advance. It does not establish superiority over omalizumab. Both groups had stopped treatment, so the week-28 finding also does not show an advantage over continued omalizumab dosing. Longer follow-up needs to establish how consistently relief persists and when patients require retreatment.
Broader evidence also matters. Larger trials across additional populations would help establish whether the benefit holds and detect uncommon adverse events. Lasting symptom control remains different from a permanent cure.
Funding matters for Cue Biopharma, Inc.. Its August financial update reported $17.4 million in cash and equivalents at June 30, followed by a private placement generating $50 million in gross proceeds. That financing supports development, while the size, duration, and cost of the next trial will determine additional capital needs.
Hedge Fund Sentiment
The filings available so far reflect positions held before Cue Biopharma, Inc. reported its CUE-221 Phase 2 results. Insider Monkey’s database showed 10 hedge funds holding the company at the end of 2Q2026, up from 4 funds three months earlier.
Conclusion
Cue Biopharma, Inc. has a positive placebo-controlled result and a potentially valuable durability advantage to test. Our view is that the evidence supports further development. Confirming sustained efficacy, safety, and a practical dosing schedule in a larger study would strengthen the case for challenging established treatment.
READ NEXT: Pan American Silver (PAAS) Updates its Reserve Base. How Much Growth Reflects Better Mines? and Lennar (LEN) Cuts Delivery Forecast. Can Construction Savings Offset Heavy Incentives?
This article is originally published at Insider Monkey.
